Literature DB >> 10372822

Adenosine mediates relaxation of human small resistance-like coronary arteries via A2B receptors.

B K Kemp1, T M Cocks.   

Abstract

1. The receptor subtype and mechanisms underlying relaxation to adenosine were examined in human isolated small coronary arteries contracted with the thromboxane A2 mimetic, 1,5,5-hydroxy-11alpha, 9alpha-(epoxymethano)prosta-5Z, 13E-dienoic acid (U46619) to approximately 50% of their maximum contraction to K+ (125 mM) depolarization (Fmax). Relaxations were normalized as percentages of the 50% Fmax contraction. 2. Adenosine caused concentration-dependent relaxations (pEC50, 5.95+/-0.20; maximum relaxation (Rmax), 96.7+/-1.4%) that were unaffected by either combined treatment with the nitric oxide inhibitors, NG-nitro-L-arginine (L-NOARG; 100 microM) and oxyhaemoglobin (HbO; 20 microM) or the ATP-dependent K+ channel (KATP) inhibitor, glibenclamide (10 microM). The pEC50 but not Rmax to adenosine was significantly reduced by high extracellular K+ (30 mM). Relaxations to the adenylate cyclase activator, forskolin, however, were unaffected by high K+ (30 mM). 3. Adenosine and a range of adenosine analogues, adenosine, 2-chloroadenosine (2-CADO), 5'-N-ethyl-carboxamidoadenosine (NECA), R(-)-N6-(2-phenylisopropyl)-adenosine (R-PIA), S(+)-N6-(2-phenylisopropyl)-adenosine (S-PIA), N6-cyclopentyladenosine (CPA), 1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-N-methyl-beta- D-ribofuranuronamide (IB-MECA), 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamido adenosine hydrochloride (CGS 21680), relaxed arteries with a rank order of potency of NECA= 2-CADO >adenosine= IB-MECA = R-PIA= CPA > S-PIA)> CGS 21680. 4. Sensitivity but not Rmax to adenosine was significantly reduced approximately 80 and 20 fold by the non-selective adenosine receptor antagonist, 8-(p-sulphophenyl)theophylline (8-SPT) and the A2 receptor antagonist, 3,7-dimethyl-1-propargylxanthine (DMPX). By contrast, the A1-selective antagonist, 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) had no effect on pEC50 or Rmax to adenosine. 5. These results suggest that A2B receptors mediate relaxation to adenosine in human small coronary arteries which is independent of NO but dependent in part on a K+-sensitive mechanism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10372822      PMCID: PMC1581442          DOI: 10.1038/sj.bjp.0702462

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  33 in total

Review 1.  Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology.

Authors:  J C Shryock; L Belardinelli
Journal:  Am J Cardiol       Date:  1997-06-19       Impact factor: 2.778

2.  Relative agonist potencies of C2-substituted analogues of adenosine: evidence for adenosine A2B receptors in the guinea pig aorta.

Authors:  P L Martin
Journal:  Eur J Pharmacol       Date:  1992-06-05       Impact factor: 4.432

3.  Impact of coronary risk factors on contribution of nitric oxide and adenosine to metabolic coronary vasodilation in humans.

Authors:  T Minamino; M Kitakaze; Y Matsumura; K Nishida; Y Kato; K Hashimura; Y Matsu-Ura; H Funaya; H Sato; T Kuzuya; M Hori
Journal:  J Am Coll Cardiol       Date:  1998-05       Impact factor: 24.094

Review 4.  Current state of purinoceptor research.

Authors:  G Burnstock
Journal:  Pharm Acta Helv       Date:  1995-03

5.  Identification of adenosine A2 receptor-cAMP system in human aortic endothelial cells.

Authors:  T Iwamoto; S Umemura; Y Toya; T Uchibori; K Kogi; N Takagi; M Ishii
Journal:  Biochem Biophys Res Commun       Date:  1994-03-15       Impact factor: 3.575

Review 6.  The role of adenosine in the regulation of coronary blood flow.

Authors:  R M Berne
Journal:  Circ Res       Date:  1980-12       Impact factor: 17.367

7.  Binding of the novel nonxanthine A2A adenosine receptor antagonist [3H]SCH58261 to coronary artery membranes.

Authors:  L Belardinelli; J C Shryock; J Ruble; A Monopoli; S Dionisotti; E Ongini; D M Dennis; S P Baker
Journal:  Circ Res       Date:  1996-12       Impact factor: 17.367

8.  The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosine receptor antagonist.

Authors:  S M Poucher; J R Keddie; P Singh; S M Stoggall; P W Caulkett; G Jones; M G Coll
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

9.  A role for mast cells in adenosine A3 receptor-mediated hypotension in the rat.

Authors:  J P Hannon; H J Pfannkuche; J R Fozard
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

10.  Adenosine activates ATP-sensitive potassium channels in arterial myocytes via A2 receptors and cAMP-dependent protein kinase.

Authors:  T Kleppisch; M T Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

View more
  24 in total

1.  Contributions of A2A and A2B adenosine receptors in coronary flow responses in relation to the KATP channel using A2B and A2A/2B double-knockout mice.

Authors:  Maryam Sharifi Sanjani; Bunyen Teng; Thomas Krahn; Stephen Tilley; Catherine Ledent; S Jamal Mustafa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-09-23       Impact factor: 4.733

2.  Differential coronary microvascular exchange responses to adenosine: roles of receptor and microvessel subtypes.

Authors:  Jianjie Wang; Stevan P Whitt; Leona J Rubin; Virginia H Huxley
Journal:  Microcirculation       Date:  2005-06       Impact factor: 2.628

3.  Contribution of adenosine A(2A) and A(2B) receptors to ischemic coronary dilation: role of K(V) and K(ATP) channels.

Authors:  Zachary C Berwick; Gregory A Payne; Brandon Lynch; Gregory M Dick; Michael Sturek; Johnathan D Tune
Journal:  Microcirculation       Date:  2010-11       Impact factor: 2.628

Review 4.  Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology.

Authors:  S Jamal Mustafa; R Ray Morrison; Bunyen Teng; Amir Pelleg
Journal:  Handb Exp Pharmacol       Date:  2009

5.  Adenosine- and hypoxia-induced dilation of human coronary resistance arteries: evidence against the involvement of K(ATP) channels.

Authors:  Fiona M Lynch; Clare Austin; Anthony M Heagerty; Ashley S Izzard
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 6.  Cardiac purinergic signalling in health and disease.

Authors:  Geoffrey Burnstock; Amir Pelleg
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

Review 7.  Regulation of Coronary Blood Flow.

Authors:  Adam G Goodwill; Gregory M Dick; Alexander M Kiel; Johnathan D Tune
Journal:  Compr Physiol       Date:  2017-03-16       Impact factor: 9.090

8.  Mechanisms involved in the adenosine-induced vasorelaxation to the pig prostatic small arteries.

Authors:  Ana S F Ribeiro; Vítor S Fernandes; Luis M Orensanz; María Pilar Martínez; Paz Recio; Ana Martínez-Sáenz; Belén Climent; Jose Luis Arteaga; Albino García-Sacristán; Dolores Prieto; Medardo Hernández
Journal:  Purinergic Signal       Date:  2011-05-13       Impact factor: 3.765

9.  Adenosine concentration in the porcine coronary artery wall and A2A receptor involvement in hypoxia-induced vasodilatation.

Authors:  Ole Frøbert; Gesine Haink; Ulf Simonsen; Claus H Gravholt; Max Levin; Andreas Deussen
Journal:  J Physiol       Date:  2005-11-10       Impact factor: 5.182

10.  Recent improvements in the development of A(2B) adenosine receptor agonists.

Authors:  Pier Giovanni Baraldi; Mojgan Aghazadeh Tabrizi; Francesca Fruttarolo; Romeo Romagnoli; Delia Preti
Journal:  Purinergic Signal       Date:  2009-01-31       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.